Siddharth Mittal, CEO & MD, Biocon, On Q4 Earnings, Pharma Market & Plans For Overseas Markets

#Q4Results #Pharma #Biocon #BioconShares #BioconBiosimilars
In Q4FY24, our Total Consolidated Revenue grew by 1% year-on-year (YoY) to Rs 3,966 crore. Core EBITDA reached Rs 1,176 crore, maintaining core operating margins at 30%. Net R&D investments were Rs 246 crore, accounting for 8% of revenue excluding Syngene. The quarter's EBITDA was Rs 964 crore, representing a 24% EBITDA margin. Profit Before Tax and exceptional items stood at Rs 328 crore. Net Profit before exceptional items was Rs 144 crore, with a reported Net Profit of Rs 136 crore. Siddharth Mittal, CEO & MD, Biocon speaks to Business Today TV's Sakshi Batra on Q4 earnings, Phrama sector and growth plans for FY25 and expansion plans for FY25.
-----------------------
Thank You for watching! Do not forget to Like | Comment | Share
-----------------------
About the channel
Watch us for the best news and views on business, stock markets, crypto currencies, consumer technology, the world of real estate, bullion, automobiles, start-ups and unicorns and personal finance. Business Today TV will also bring you all you need to know about mutual funds, insurance, loans and pension plans among others.
Follow us at:
Website: www.businesstoday.in
WhatsApp: whatsapp.com/channel/0029Va4Hd309hXFCqY62yD2I
Facebook: / businesstoday
twitter: / business_today
Instagram: / business_today